Thus, even though ibrutinib was recently approved by the Food and Drug Administration for the treatment of de novo 17p-deleted CLL, it remains unknown how, and to what extent, ibrutinib confers a survival benefit in p53-mutated CLL. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.